Bank of America’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
Sell
-27,300
Closed -$2.51M 8444
2021
Q1
$2.51M Buy
+27,300
New +$2.3M ﹤0.01% 4055
2020
Q4
Sell
-37,500
Closed -$2.91M 7623
2020
Q3
$2.91M Hold
37,500
﹤0.01% 3391
2020
Q2
$2.08M Hold
37,500
﹤0.01% 3593
2020
Q1
$1.11M Buy
+37,500
New +$1.27M ﹤0.01% 3947
2019
Q3
Sell
-100,000
Closed -$2.41M 7760
2019
Q2
$2.41M Buy
+100,000
New +$2.54M ﹤0.01% 3889
2018
Q1
Sell
-11,800
Closed -$172K 7485
2017
Q4
$172K Buy
+11,800
New +$166K ﹤0.01% 5484
2017
Q3
Sell
-250,000
Closed -$2.97M 7420
2017
Q2
$2.97M Hold
250,000
﹤0.01% 3525
2017
Q1
$3.69M Buy
+250,000
New +$4.05M ﹤0.01% 3314
2016
Q2
Sell
-40,300
Closed -$668K 7555
2016
Q1
$668K Buy
+40,300
New +$705K ﹤0.01% 4410

Other funds holding HZNP

Bank of America's HZNP Position: Q4 2023 in Review

Bank of America sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 1,025,402 shares — an estimated $119M sold.

Bank of America first reported a position in HZNP in Q2 2013 and held it in 42 quarters. The position peaked at $260M in Q1 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Bank of America reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Bank of America sold 1,025,402 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $119M.
  • Bank of America first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2013 and held it in 42 quarters.
  • Bank of America's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $260M in Q1 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Bank of America's 13F filing for Q4 2023, filed 14 Feb 2024.